首页   按字顺浏览 期刊浏览 卷期浏览 Phase I Evaluation of Preirradiation Chemotherapy with Carmustine and Cisplatin and Acc...
Phase I Evaluation of Preirradiation Chemotherapy with Carmustine and Cisplatin and Accelerated Radiation Therapy in Patients with High-grade Gliomas

 

作者: S. Rajkumar,   Jan Buckner,   Paula Schomberg,   Henry Pitot,   James Ingle,   Terrence Cascino,  

 

期刊: Neurosurgery  (OVID Available online 1999)
卷期: Volume 44, issue 1  

页码: 67-73

 

ISSN:0148-396X

 

年代: 1999

 

出版商: OVID

 

关键词: Anaplastic astrocytoma;BCNU;Brain tumors;Chemotherapy;Cisplatin;Glioblastoma;Radiation therapy

 

数据来源: OVID

 

摘要:

OBJECTIVE:A Phase I study was conducted to determine the safety, toxicity, and maximum tolerated dose of preirradiation chemotherapy using carmustine (BCNU) and cisplatin in the treatment of high-grade gliomas.METHODS:Patients with newly diagnosed high-grade gliomas received BCNU and cisplatin after surgery, both before and during definitive radiation therapy. Preirradiation chemotherapy consisted of an administration of 40 mg/m2BCNU on Days 1 through 3 and 30 mg/m2cisplatin on Days 1 through 3 and 29 through 31 and repeated at 8 weeks to coincide with the start of radiation therapy. Postradiation chemotherapy consisted of an administration of 200 mg/m2BCNU once every 8 weeks for four cycles. Radiation therapy consisted of 160-cGy fractions administered twice daily for 15 days, yielding a total dose of 4800 cGy. Dose escalation of BCNU was planned. If hematological toxicity was mild, the dose of cisplatin was to be held constant and BCNU dose escalated to 50 mg/m2on Days 1 through 3.RESULTS:Eighteen patients were studied. The hematological toxicity was dose-limiting. Grade 3 or 4 leukopenia occurred in each of 10 patients (56%), and Grade 3 or 4 thrombocytopenia occurred in each of 9 patients (50%). Other toxicities included anorexia (94%), nausea (83%), emesis (33%), alopecia (94%), mild ototoxicity (50%), and, in one patient, death as a result of BCNU pulmonary toxicity. The median survival time was 14 months. Objective responses occurred in 45% of the patients evaluable for response. The maximum tolerated dose of this combination was 50 mg/m2BCNU on Days 1 through 3 and 30 mg/m2cisplatin on Days 1 through 3 and 29 through 31 before radiation and repeated in 8 weeks to coincide with the start of radiation.CONCLUSION:This schedule of the preirradiation administration of BCNU and cisplatin with accelerated hyperfractionated radiation therapy for the treatment of high-grade gliomas provides a less toxic alternative to that of previous studies of preirradiation chemotherapy with these agents and merits further investigation.

 



返 回